JP2023511441A - Ｇｉｐ／ｇｌｐ１共アゴニスト化合物 - Google Patents

Ｇｉｐ／ｇｌｐ１共アゴニスト化合物 Download PDF

Info

Publication number
JP2023511441A
JP2023511441A JP2022544753A JP2022544753A JP2023511441A JP 2023511441 A JP2023511441 A JP 2023511441A JP 2022544753 A JP2022544753 A JP 2022544753A JP 2022544753 A JP2022544753 A JP 2022544753A JP 2023511441 A JP2023511441 A JP 2023511441A
Authority
JP
Japan
Prior art keywords
ethoxy
glu
amino
acetyl
carboxyphenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022544753A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511441A5 (https=
JPWO2021150673A5 (https=
Inventor
アルシナ－フェルナンデス，ホルヘ
アンドリュー ブラウン，ロバート
チャドウィック カミンズ，ロバート
エルサイード ハメド エルサイード，モハメド
レネー ガイザー，アンドレア
ライ，シャンイン
チュイ，ホンチャン
モーガン ワトソン，ブライアン
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2023511441A publication Critical patent/JP2023511441A/ja
Publication of JP2023511441A5 publication Critical patent/JP2023511441A5/ja
Publication of JPWO2021150673A5 publication Critical patent/JPWO2021150673A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
JP2022544753A 2020-01-23 2021-01-21 Ｇｉｐ／ｇｌｐ１共アゴニスト化合物 Pending JP2023511441A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062964932P 2020-01-23 2020-01-23
US62/964,932 2020-01-23
PCT/US2021/014302 WO2021150673A1 (en) 2020-01-23 2021-01-21 Gip/glp1 co-agonist compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025195273A Division JP2026069790A (ja) 2020-01-23 2025-11-14 Ｇｉｐ／ｇｌｐ１共アゴニスト化合物

Publications (3)

Publication Number Publication Date
JP2023511441A true JP2023511441A (ja) 2023-03-17
JP2023511441A5 JP2023511441A5 (https=) 2024-01-25
JPWO2021150673A5 JPWO2021150673A5 (https=) 2024-01-25

Family

ID=74592824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022544753A Pending JP2023511441A (ja) 2020-01-23 2021-01-21 Ｇｉｐ／ｇｌｐ１共アゴニスト化合物

Country Status (13)

Country Link
US (1) US20230265151A1 (https=)
EP (1) EP4093757A1 (https=)
JP (1) JP2023511441A (https=)
KR (1) KR20220131292A (https=)
CN (1) CN115298207A (https=)
AR (1) AR121093A1 (https=)
AU (1) AU2021211451B2 (https=)
BR (1) BR112022014397A2 (https=)
CA (1) CA3165430A1 (https=)
IL (1) IL294955A (https=)
MX (1) MX2022009149A (https=)
TW (1) TWI770781B (https=)
WO (1) WO2021150673A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI912614B (zh) * 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
JP2024508745A (ja) * 2021-02-17 2024-02-28 イーライ リリー アンド カンパニー Ｇｉｐ／ｇｌｐ１デュアルアゴニスト治療方法
IL310377A (en) 2021-08-30 2024-03-01 Mindrank Ai Ltd Novel aryl ether substituted heterocyclic compound as glp1r agonist
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
CN117586373A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效双激动剂化合物
CN116023444B (zh) * 2022-08-12 2023-08-01 重庆宸安生物制药有限公司 一种gip和glp-1双受体激动剂多肽化合物及其应用
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523647A (ja) * 2010-03-26 2013-06-17 イーライ リリー アンド カンパニー 新規ペプチドならびにそれらを調製および使用するための方法
JP2016540741A (ja) * 2013-11-06 2016-12-28 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
JP2017507124A (ja) * 2015-01-09 2017-03-16 イーライ リリー アンド カンパニー Ｇｉｐおよびｇｌｐ−１コアゴニスト化合物
JP2018521043A (ja) * 2015-06-22 2018-08-02 イーライ リリー アンド カンパニー グルカゴン及びｇｌｐ−１共アゴニスト化合物
JP2021508731A (ja) * 2018-07-23 2021-03-11 イーライ リリー アンド カンパニー Ｇｉｐ／ｇｌｐ１共アゴニスト化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012167744A1 (en) * 2011-06-10 2012-12-13 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
JP6228187B2 (ja) * 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
HK1211232A1 (en) * 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523647A (ja) * 2010-03-26 2013-06-17 イーライ リリー アンド カンパニー 新規ペプチドならびにそれらを調製および使用するための方法
JP2016540741A (ja) * 2013-11-06 2016-12-28 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
JP2017507124A (ja) * 2015-01-09 2017-03-16 イーライ リリー アンド カンパニー Ｇｉｐおよびｇｌｐ−１コアゴニスト化合物
JP2018521043A (ja) * 2015-06-22 2018-08-02 イーライ リリー アンド カンパニー グルカゴン及びｇｌｐ−１共アゴニスト化合物
JP2021508731A (ja) * 2018-07-23 2021-03-11 イーライ リリー アンド カンパニー Ｇｉｐ／ｇｌｐ１共アゴニスト化合物

Also Published As

Publication number Publication date
IL294955A (en) 2022-09-01
US20230265151A1 (en) 2023-08-24
TW202140528A (zh) 2021-11-01
EP4093757A1 (en) 2022-11-30
AU2021211451B2 (en) 2023-11-02
WO2021150673A1 (en) 2021-07-29
KR20220131292A (ko) 2022-09-27
AR121093A1 (es) 2022-04-20
TWI770781B (zh) 2022-07-11
BR112022014397A2 (pt) 2022-10-11
MX2022009149A (es) 2022-12-15
AU2021211451A1 (en) 2022-08-18
CA3165430A1 (en) 2021-07-29
CN115298207A (zh) 2022-11-04

Similar Documents

Publication Publication Date Title
JP7626530B2 (ja) Ｇｉｐ／ｇｌｐ１共アゴニスト化合物
JP2023511441A (ja) Ｇｉｐ／ｇｌｐ１共アゴニスト化合物
JP7658877B2 (ja) インクレチン類似体およびその使用
AU2022231763B2 (en) Protein tyrosine-tyrosine analogs and methods of using the same
JP7521027B2 (ja) Ｇｉｐｒアゴニスト化合物
JP2022031787A (ja) グルカゴン及びｇｌｐ－１共アゴニスト化合物
JP2023506952A (ja) インクレチン類似体およびその使用
EP4587462A1 (en) Gip and glp-1 dual agonist compounds
JP2026069790A (ja) Ｇｉｐ／ｇｌｐ１共アゴニスト化合物
HK40127005A (zh) 蛋白酪氨酸-酪氨酸类似物及其使用方法
EA052413B1 (ru) Соединения-коагонисты gip/glp-1
EA048422B1 (ru) Соединения-коагонисты gip/glp1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250418

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250715